Iodine uptake restoration in thyroid cancer

Details Iodine uptake restoration in thyroid cancer Iodine uptake restoration in thyroid cancer

2006-04-18

2006-04-18

Canella, Karen A. (Department: 1643)

Chemistry: molecular biology and microbiology

Micro-organism, tissue cell culture or enzyme using process...

Using tissue cell culture to make a protein or polypeptide

C435S375000, C435S377000

Reexamination Certificate

active

07029879

ABSTRACT:
A method of expressing a tumor specific therapeutic response element in a cancerous cell is disclosed in which the response element was previously blocked from expression. The method comprises the step of administering an unblocking agent to the cancerous cell harboring a gene encoding the response element, thereby resulting in the expression of the response element.

REFERENCES:
Schmutzler, C, et al, 1997, Retinoic acid increases sodium/iodide symporter mRNA levels in human thyroid cancer cell lines and suppresses expression of functional symporter in nontransformed FRTL-5, Biochem. Biophys. Res. Commun., vol. 240, pp. 832-838.
Avvedimento, EV, et al, 1989, Reactivation of thyroglobulin gene expression in transformed thyroid cells by 5-azacytidine, Cell, vol. 58, pp. 1135-1142.
Spath, GF, et al, Hepatocyte nuclear factor 4 expression overcomes repression of the hepatic phenotype in dedifferentiated hepatoma cells, Molecular and Cellular Biology, vol. 17, pp. 1913-1922.
Van Herle, AJ, et al, 1990, Effects of 13 cis-retinoic acid on growth and differentiation of human follicular carcinoma cells (UCLA RO 82 W-1) in vitro, Journal of Clinical Endocrinology and Metabolism, vol. 71, pp. 755-763.
Swafford, DS, et al, 1997, Frequent aberrant methylation of p16-INK4a in primary rat lung tumors, Molecular and Cellular Biology, vol. 17, pp. 1366-1374.
Grunwald, F, et al, 1998, Redifferentiation therapy with retinoic acid in follicular thyroid cancer, Journal of Nuclear Medicine, vol. 39, pp. 1555-1558.
Simon, D, et al, 1998, Redifferentiation therapy with retinoids: therapeutic option for advanced follicular and papillary thyroid carcinoma, World Journal of Surgery, vol. 22, pp. 569-574.
Venkataraman, G, et al, 1999, Restoration of iodide uptake in dedifferentiated thyroid carcinoma: relationship to human NA+/I−symporter gene methylation status, vol. 84, pp. 2449-2457.
Kleef, J, et al, 1998, The helix-loop-helix protein Id2 is overexpressed in human pancreatic cancer, Cancer Research, vol. 58, pp 3769-3772.
Thomas, GA, et al, 1992, Production of thyroid tumors in mice by demethylating agents, Carcinogenesis, vol. 13, pp. 1039-1042.
Matsuda, A, et al, 1997, A homozygous missense mutation of the sodium/iodide symporter gene causing iodide transport defect, Journal of Clinical Endocrinology and Metabolism, vol. 82, pp. 3966-3971.
Vivaldi, A, et al, 2000, Sodium/iodide symporter gene transcript expression is not correlated with the scintigraphic imaging of both primary and metastatic thyroid tissues, Journal of Endocrinological Investigation, vol. 23, pp. 24 (meeting abstract).
Graff, JR, et al, 1998, Distinct patterns of E-cadherin CpG island methylation in papillary, follicular, Hurthle's cell, and poorly differentiated human thyroid carcinoma, Cancer Research, vol. 58, pp. 2063-2066.
Ormandy, CJ, et al, 1992, Transcriptional regulation of prolactin receptor gene expression by sodium butyrate in MCF-7 human breast cancer cells, Endocrinology, vol. 131, pp. 982-984.
Schmitt, TL, et al, 2001, Transcriptional regulation of the human sodium/iodide symporter gene by PAX-8 and TTF-1, Expermiental and Clinical Endocrinology, vol. 109, pp. 27-31; BIOSIS database, accession No. 140752.
Behr, M, et al, 1998, Cloning of a functional promoter of the human sodium/iodide-symporter gene, Biochemistry Journal, vol. 331, pp. 359-363.
Riedel C, et al. Trends Biochem Sci Aug. 2001;26(8):490-6.
Bender et al (Pharmaceutical Research, 1998, vol. 15, pp. 175-187).
Thomas et al (Carcinogenesis, 1992, vol. 13, pp. 1039-1042).
Hancock et al (Journal of the National Cancer Institute, 1984, vol. 72, pp. 833-840).
Takenaga (International Journal of Cancer, 1984, vol. 34, pp. 83-89).
Carr et al (Cancer Research, 1987, vol. 47, pp. 4199-4201).
Cosgrove et al (Biochimica et Biophysica Acta, 1990, vol. 1087, pp. 80-86).
Jones (Trends in Genetics, 1999, vol. 15, pp. 34-37).
Nakagawa et al (Cancer Research, 1988, vol. 48, pp. 2096-2100).
The abstract of Zabel et al (Histology and Histopathology, 1997, vol. 12, pp. 283-289).
Schreck et al (Journal of Clinical Endocrinology and Metabolism, 1994, vol. 79, pp. 791-798).
Abstract of Endean et al (FASEB Journal, 1995, vol. 9, p. A94).
Kenneth B. Ain, Management of undifferentiated thyroid cancer, Balliere's Clinical Endocrinology and Metabolism, vol. 14, No. 4, pp. 615-629, 2000.
George J. Dover, et al., The Effects of Variable Doses of 5-Azacytidine on Fetal Hemoglobin Production in Sickle Cell Anemia, The Red Cell: Sixth Ann Arbor Conference, pp. 73-83.
Samuel Charache, et al., Treatment of sickle cell anemia with 5-azacytidine results in increased fetal hemoglobic production and is associated with nonrandom hypomethylation of DNA around the γ-δ-β-Globin gene complex, Proc. Natl. Acad. Sci. USA, vol. 80, pp. 4842-4846, Aug. 1983, Medical Sciences.
Timothy J. Ley, et al. , 5-Azacytidine Selectively Increases γ-Globin Synthesis in a Patient With β+Thalassemia- The New England Journal of Medicine, vol. 307, No. 24.
Timothy J. Ley, DNA Methylation and Globin Gene Expression in Patients Treated with 5-Azacytidine, Globin Gene Expression and Hemotopoietic Differentiation, pp. 457-474.

Affiliated with

Also associated with

Rating

Iodine uptake restoration in thyroid cancer does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Iodine uptake restoration in thyroid cancer, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Iodine uptake restoration in thyroid cancer will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3558202